{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    8,
    11,
    105,
    106,
    108
  ],
  "modelUsed": "claude-opus-4-5",
  "advanced": {
    "studyAmendments": [
      {
        "id": "amend_1",
        "number": "a",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "The overall rationale for the amendment is to provide clarifications in the protocol related to schedule of activities, administration of the investigational product namely subcutaneous (SC) ramucirumab and chemotherapy (FOLFIRI) as discussed below. There are no changes in the study-design, inclusion/exclusion criteria, or statistical analysis that would impact participant safety and overall objectives of the study.",
        "effectiveDate": "2020-09-14",
        "reasonIds": [
          "ar_1_1",
          "ar_1_2"
        ],
        "previousVersion": "Original Protocol",
        "newVersion": "a"
      },
      {
        "id": "amend_2",
        "number": "b",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "The overall rationale for the amendment is to incorporate changes and provide additional clarifications according to regulatory agency interactions.",
        "effectiveDate": "2020-10-02",
        "reasonIds": [
          "ar_2_1"
        ],
        "previousVersion": "a",
        "newVersion": "b"
      },
      {
        "id": "amend_3",
        "number": "c",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "The overall rationale for the amendment is to incorporate updates for hepatic safety and to allow participants to adjust their weekly maintenance dose to the maintenance dose of Cohort C once the dose has been confirmed.",
        "effectiveDate": "2020-11-05",
        "reasonIds": [
          "ar_3_1",
          "ar_3_2"
        ],
        "previousVersion": "b",
        "newVersion": "c"
      },
      {
        "id": "amend_4",
        "number": "d",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "The overall rationale for the amendment is to make changes based on preliminary data from Study JVDT, to remove hepatocellular carcinoma (HCC) and gastric cancer patients from inclusion in Cohort A and add to Cohorts B and C, and to correct an error in the contraceptive language.",
        "effectiveDate": "2021-01-14",
        "reasonIds": [
          "ar_4_1",
          "ar_4_2",
          "ar_4_3"
        ],
        "previousVersion": "c",
        "newVersion": "d"
      },
      {
        "id": "amend_5",
        "number": "e",
        "scope": {
          "code": "Global",
          "codeSystem": "USDM",
          "decode": "Global"
        },
        "instanceType": "StudyAmendment",
        "summary": "The overall rationale for the amendment is to enable investigation of additional dosage regimens. Preliminary interim analysis data from Study I4T-MC-JVDT, a single-site study in healthy participants who received a single dose of SC or IV ramucirumab indicated a 40% bioavailability for ramucirumab following SC administration (bioavailability previously predicted: >50%). A Sub-Cohort B1 has been added to provide a second-dose level (in addition to cohort A), with the goal to generate PK data from at least 6 participants to inform dosing strategy for Sub-Cohort B2 (loading dose and maintenance weekly dose).",
        "effectiveDate": "2021-02-26",
        "reasonIds": [
          "ar_5_1",
          "ar_5_2"
        ],
        "previousVersion": "d",
        "newVersion": "e"
      }
    ],
    "amendmentReasons": [
      {
        "id": "ar_1_1",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_1_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_2_1",
        "code": "REGULATORY",
        "description": "Regulatory",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_1",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_3_2",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_2",
        "code": "SAFETY",
        "description": "Safety",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_4_3",
        "code": "ADMINISTRATIVE",
        "description": "Administrative",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_1",
        "code": "SCIENTIFIC",
        "description": "Scientific",
        "instanceType": "AmendmentReason"
      },
      {
        "id": "ar_5_2",
        "code": "OPERATIONAL",
        "description": "Operational",
        "instanceType": "AmendmentReason"
      }
    ],
    "countries": [
      {
        "id": "country_1",
        "name": "United States",
        "instanceType": "Country",
        "code": "US"
      }
    ],
    "studySites": [],
    "summary": {
      "amendmentCount": 5,
      "countryCount": 1,
      "siteCount": 0
    },
    "geographicScope": {
      "id": "geo_1",
      "name": "Study Geographic Scope",
      "scopeType": "National",
      "instanceType": "GeographicScope",
      "countryIds": [
        "country_1"
      ],
      "regions": [
        "North America"
      ]
    }
  },
  "rawResponse": {
    "amendments": [
      {
        "number": "a",
        "effectiveDate": "2020-09-14",
        "summary": "The overall rationale for the amendment is to provide clarifications in the protocol related to schedule of activities, administration of the investigational product namely subcutaneous (SC) ramucirumab and chemotherapy (FOLFIRI) as discussed below. There are no changes in the study-design, inclusion/exclusion criteria, or statistical analysis that would impact participant safety and overall objectives of the study.",
        "previousVersion": "Original Protocol",
        "newVersion": "a",
        "reasons": [
          "Administrative",
          "Operational"
        ]
      },
      {
        "number": "b",
        "effectiveDate": "2020-10-02",
        "summary": "The overall rationale for the amendment is to incorporate changes and provide additional clarifications according to regulatory agency interactions.",
        "previousVersion": "a",
        "newVersion": "b",
        "reasons": [
          "Regulatory"
        ]
      },
      {
        "number": "c",
        "effectiveDate": "2020-11-05",
        "summary": "The overall rationale for the amendment is to incorporate updates for hepatic safety and to allow participants to adjust their weekly maintenance dose to the maintenance dose of Cohort C once the dose has been confirmed.",
        "previousVersion": "b",
        "newVersion": "c",
        "reasons": [
          "Safety",
          "Administrative"
        ]
      },
      {
        "number": "d",
        "effectiveDate": "2021-01-14",
        "summary": "The overall rationale for the amendment is to make changes based on preliminary data from Study JVDT, to remove hepatocellular carcinoma (HCC) and gastric cancer patients from inclusion in Cohort A and add to Cohorts B and C, and to correct an error in the contraceptive language.",
        "previousVersion": "c",
        "newVersion": "d",
        "reasons": [
          "Scientific",
          "Safety",
          "Administrative"
        ]
      },
      {
        "number": "e",
        "effectiveDate": "2021-02-26",
        "summary": "The overall rationale for the amendment is to enable investigation of additional dosage regimens. Preliminary interim analysis data from Study I4T-MC-JVDT, a single-site study in healthy participants who received a single dose of SC or IV ramucirumab indicated a 40% bioavailability for ramucirumab following SC administration (bioavailability previously predicted: >50%). A Sub-Cohort B1 has been added to provide a second-dose level (in addition to cohort A), with the goal to generate PK data from at least 6 participants to inform dosing strategy for Sub-Cohort B2 (loading dose and maintenance weekly dose).",
        "previousVersion": "d",
        "newVersion": "e",
        "reasons": [
          "Scientific",
          "Operational"
        ]
      }
    ],
    "geographicScope": {
      "type": "National",
      "countries": [
        {
          "name": "United States",
          "code": "US"
        }
      ],
      "regions": [
        "North America"
      ],
      "plannedSites": null
    },
    "sites": []
  }
}